Abstract
Purpose
Type 2 diabetes mellitus (T2DM) patients treated with metformin are predisposed to develop contrast-induced nephropathy (CIN) after received emergency contrast-enhanced computed tomography (CT) examination. We evaluated the protective effects of alprostadil on CIN in T2DM patients treated with metformin after contrast media (CM) administration.
Methods
In this single-institution, single-blind, superiority trial, we randomly assigned 451 T2DM patients taking metformin and underwent emergency contrast-enhanced CT examination to either the alprostadil group (227 patients) receiving alprostadil or the control group (224 patients) without alprostadil. All subjects stopped taking metformin and drank 500 ml water within 12 h after CM exposure. In addition, patients in the alprostadil group were injected with alprostadil (10 μg/day, for 3 days) plus 20 ml normal saline (alprostadil hydration) and the control group patients were daily injected with 20 ml normal saline as control for 3 days following CM administration. Serum creatinine (Scr) was measured before and <72 h after contrast-enhanced CT examination. CIN was defined as an increase in Scr ≥ 44.2 µmol/l (0.5 mg/dL) or >25% over baseline within 3 days of contrast administration.
Results
There was a lower incidence of CIN in patients underwent alprostadil hydration than drinking water monohydration after CM administration, who with either normal renal function or chronic kidney disease (baseline eGFR < 60 ml·min−1·1.73 m−2).
Conclusions
Alprostadil hydration was superior to drinking water monohydration regarding preventing CIN in T2DM patients treated with metformin after contrast-enhanced CT.
Similar content being viewed by others
References
Solomon R, Dauerman HL (2010) Contrast-induced acute kidney injury. Circulation 122(23):2451–2455
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105(19):2259–2264
Berg KJ (2000) Nephrotoxicity related to contrast media. Scand J Urol Nephrol 34(5):317–322
Sudarsky D, Nikolsky E (2011) Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis 4:85–99
Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P et al (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170(21):1892–1899
Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG et al (2011) Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 6(5):1032–1040
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312(24):2668–2675
Posma RA, Lexis CP, Lipsic E, Nijsten MW, Damman K, Touw DJ, van Veldhuisen DJ, van der Harst P, van der Horst IC (2015) Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: data from the GIPS-III Trial. Cardiovasc Drugs Ther 29(5):451–459
Ad hoc working group, Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W (2012) A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27(12):4263–4272
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almen T et al (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21(12):2527–2541
Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ (2014) Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J 65(2):96–105
American College of Radiology (2017) ACR manual on contrast media, version 10.2 https://www.acr.org/Quality-Safety/Resources/Contrast-Manual. Accessed Mar14
Wu MY, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, Bai CH, Hsu YH, Lin YF, Tam KW (2013) The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol 45(5):1309–1318
Sharma D (2012) Hydration is critical for prevention of contrast-induced nephropathy. JACC Cardiovasc Interv 5(4):454–455
Firouzi A, Eshraghi A, Shakerian F, Sanati HR, Salehi N, Zahedmehr A, Kiani R, Madani M, Pedarzadeh A (2012) Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients. Int Urol Nephrol 44(4):1145–1149
Li Y, Liu Y, Fu L, Mei C, Dai B (2012) Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS ONE 7(4):e34450
Briguori C, Airoldi F, D’Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I et al (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115(10):1211–1217
Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH et al (2009) N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 157(3):576–583
Koch JA, Plum J, Grabensee B, Modder U (2000) Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 15(1):43–49
Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F, Brinker J (2001) Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 8(3):155–162
Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, Yuan R et al (2009) Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 103(4):512–514
Verges B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G et al (2012) Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Arch Cardiovasc Dis 105(4):239–253
Morcos SK, Thomsen HS (2003) European Society of Urogenital Radiology guidelines on administering contrast media. Abdom Imaging 28(2):187–190
Miao Y, Zhong Y, Yan H, Li W, Wang BY, Jin J (2013) Alprostadil plays a protective role in contrast-induced nephropathy in the elderly. Int Urol Nephrol 45(4):1179–1185
Xu RH, Ma GZ, Cai ZX, Chen P, Zhu ZD, Wang WL (2013) Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients. Exp Ther Med 6(4):863–867
Li WH, Li DY, Qian WH, Liu JL, Xu TD, Zhu H, He HY (2014) Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention. Int Urol Nephrol 46(4):781–786
Borbely Z (2016) Chronic kidney diseases, metformin and lactic acidosis. Vnitr Lek 62(4):299–303
Briguori C, Tavano D, Colombo A (2003) Contrast agent–associated nephrotoxicity. Prog Cardiovasc Dis 45(6):493–503
Itoh Y, Yano T, Sendo T, Oishi R (2005) Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci 97(4):473–488
Kritsch D, Hutter HP, Hirschl M, Katzenschlager R (2006) Persistent sciatic artery: an uncommon cause of intermittent claudication. Int Angiol 25(3):327–329
Ikeda S, Kobayashi M, Fukuhara S, Esato K (2006) Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. Int Angiol 25(2):169–174
Paller MS, Manivel JC (1992) Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 42(6):1345–1354
Gurkowski L, MacDougall M, Wiegmann T (1995) Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther 2(11):837–842
Spargias K, Adreanides E, Demerouti E, Gkouziouta A, Manginas A, Pavlides G, Voudris V, Cokkinos DV (2009) Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 120(18):1793–1799
Eisenberg RL, Bank WO, Hedgock MW (1981) Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 136(5):859–861
Zeller M, Labalette-Bart M, Juliard JM, Potier L, Feldman LJ, Steg PG, Cottin Y, Roussel R (2016) Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: amulticenter study. Int J Cardiol 220:137–142
Asif A, Cherla G, Merrill D, Cipleu CD, Tawakol JB, Epstein DL, Lenz O (2005) Venous mapping using venography and the risk of radiocontrast-induced nephropathy. Semin Dial 18(3):239–242
Ng CS, Shaw AD, Bell CS, Samuels JA (2010) Effect of IV contrast medium on renal function in oncologic patients undergoing CT in ICU. AJR Am J Roentgenol 195(2):414–422
Lufft V, Hoogestraat-Lufft L, Fels LM, Egbeyong-Baiyee D, Tusch G, Galanski M, Olbricht CJ (2002) Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 40(2):236–242
Josephson SA, Dillon WP, Smith WS (2005) Incidence of contrast nephropathy from cerebral CT angiography and CT perfusion imaging. Neurology 64(10):1805–1806
Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, Pedrosa I (2011) Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol 196(5):1094–1101
Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28(2):653–659
McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE (2014) Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 271(1):65–73
McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S, Williamson EE, Kallmes DF (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267(1):106–118
Lopez-Ruiz A, Chandrashekar K, Juncos LA (2017) Changing Paradigms in Contrast Nephropathy. J Am Soc Nephrol 28(2):397–399
Acknowledgements
We acknowledge Dr. Xiaofang Wei for helpful discussions. We also thank Danni Zhu for her assistance in experimental procedures. This work is partially supported by the key project of Qingdao Health Bureaugrant10-4-2-5-jch. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Wang, J., Ai, X., Li, L. et al. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol 49, 2019–2026 (2017). https://doi.org/10.1007/s11255-017-1639-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-017-1639-2